Erlotini Combined With Bevacizumab For Late Nonsmall Cells Analysis Of The Efficacy Of Lung Cancer

Objective To study the clinical effect of erlotinib combined with bevacizumab in the treatment of advanced non-small cell lung cancer.Methods Collected in the first people's Hospital of Chuzhou in July 2015 ~2016 year in June admitted 48 cases of patients with advanced non small cell lung cancer,both pathology,cytology,diagnosis of non small cell lung cancer,were randomly divided into observation group and control group,24 cases in control group were given gemcitabine combined cisplatin treatment,observation group of24 cases.Using erlotinib plus bevacizumab treatment,the quality of life of patients with active Karnofsky score and tumor scale(QOL)assessment of patients with clinical symptoms improved after treatment,according to the WHO standard for therapeutic effect of solid tumors(RECIST)were evaluated in two groups respectively.The therapeutic effect in the patients before and after treatment in different time,fasting the venous blood 4ml of immune function in patients with(T CD4+,CD8+,CD3+ lymphocytes,CD4/CD8)index and serum tumor markers(CA50,CEA,CYFRA21-1)level changes were recorded during treatment.The incidence of adverse reactions between the symptoms.Results 1.The observation group of 2 cases of complete remission,partial remission in 12 cases,6 cases of stable disease control rate of 83.33% was significantly higher than the control group 72.22%(P<0.05).2.The two groups before treatment,CD3+,CD4+,CD8+,CD4/CD8 was not statistically significant(P>0.05);after treatment,two groups of CD3+,CD4+,CD4/CD8 the same group was significantly lower than that before treatment,CD8+ was significantly higher than that of the same group before treatment(P<0.05,P<0.01),the observation group CD3+,CD4+,CD4/CD8 were significantly higher than the control group,CD8+was significantly lower than the control group(P<0.05).3.The serum CA50 before treatment,two groups of YFRA21-1,CEA were not statistically significant(P>0.05);treatment after two groups of serum CA50,YFRA21-1,CEA were obviously lower than those of the same group before treatment(P<0.05,P<0.01),the serum levels of CA50,YFRA21-1,CEA were significantly lower than the control group(P<0.05,P<0.01).4.According to the KPS score,QOL score standard evaluation of patients in the observation group of patients with clinical symptom improvement rate reached 72.22%(17/24),symptom improvement time was 6~17d,the average symptom improvement time was 11.35±2.11d;the control group of patients with clinical symptoms improvement rate was 45.83%(11/24),symptom improvement time was 9~23d,the average symptom improvement time was 14.28 ±2.64d;two groups were compared,the observation group in patients with clinical symptoms was better than the control group.The difference was statistically significant(P<0.05,P<0.01).5.The toxicity symptoms occurred in the patients in the observation group of erlotinib plus bevacizumab combined medication during the symptoms were mild,mainly for grade I~II degree of rash or gastrointestinal reactions,patients in the treatment period to take other special intervention can be relieved;the intervention of conventional chemotherapy the patients in the control group during drug toxicity symptoms were myelosuppression,adverse reactions of interstitial pneumonia and other more serious,and more serious in patients with gastrointestinal reaction,To reach the third degree,we need to give a specific treatment intervention.The incidence of side effects in the two groups of patients was lower than that in the control group,the difference was statistically significant(P<0.05,P<0.01).Conclusion Erlotinib plus bevacizumab therapy in the treatment of advanced non-small cell lung cancer is effective,can effectively improve the disease control effect.The efficacy of erlotinib plus bevacizumab helps regulate the immune response,reduce the serum level of tumor markers.The efficacy of erlotinib plus bevacizumab monoclonal antibody drug treatment can reduce the clinical symptoms of advanced non small cell patients with lung cancer,reduce drug adverse reactions,prolong the survival time of patients with non-small cell lung cancer in advanced stage.